NI201300083A - Inhibidores de glucosilceramida sintasa - Google Patents
Inhibidores de glucosilceramida sintasaInfo
- Publication number
- NI201300083A NI201300083A NI201300083A NI201300083A NI201300083A NI 201300083 A NI201300083 A NI 201300083A NI 201300083 A NI201300083 A NI 201300083A NI 201300083 A NI201300083 A NI 201300083A NI 201300083 A NI201300083 A NI 201300083A
- Authority
- NI
- Nicaragua
- Prior art keywords
- glucosylceramide synthase
- synthase inhibitors
- treatment
- glucosylceramide
- gcs
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
- C07D455/02—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing not further condensed quinolizine ring systems
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01022—Alpha-galactosidase (3.2.1.22)
Abstract
La invención está relacionada con inhibidores de glucosilceramida sintasa (GCS) útiles para el tratamiento de enfermedades metabólicas, tales como enfermedades de almacenamiento lisosómico, solos o en combinación con terapia de remplazo enzimático, y para el tratamiento de cáncer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161454034P | 2011-03-18 | 2011-03-18 | |
US201261590711P | 2012-01-25 | 2012-01-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
NI201300083A true NI201300083A (es) | 2014-02-28 |
Family
ID=46879977
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NI201300083A NI201300083A (es) | 2011-03-18 | 2013-09-17 | Inhibidores de glucosilceramida sintasa |
Country Status (36)
Country | Link |
---|---|
US (5) | US9139580B2 (es) |
EP (2) | EP2685986B1 (es) |
JP (2) | JP6117708B2 (es) |
KR (1) | KR101987736B1 (es) |
CN (2) | CN103917094B (es) |
AR (1) | AR085425A1 (es) |
AU (2) | AU2012231275A1 (es) |
BR (2) | BR112013023774B1 (es) |
CA (1) | CA2830540C (es) |
CL (1) | CL2013002688A1 (es) |
CO (1) | CO6801749A2 (es) |
CR (1) | CR20190034A (es) |
DK (1) | DK2685986T3 (es) |
DO (1) | DOP2013000209A (es) |
EC (1) | ECSP13012978A (es) |
ES (1) | ES2774293T3 (es) |
GT (1) | GT201300215A (es) |
HR (1) | HRP20200226T1 (es) |
HU (1) | HUE047888T2 (es) |
IL (1) | IL228514B (es) |
LT (1) | LT2685986T (es) |
MA (1) | MA35023B1 (es) |
MX (3) | MX365245B (es) |
MY (1) | MY173998A (es) |
NI (1) | NI201300083A (es) |
PE (1) | PE20140412A1 (es) |
PL (1) | PL2685986T3 (es) |
PT (1) | PT2685986T (es) |
RS (1) | RS59963B1 (es) |
RU (2) | RU2018104472A (es) |
SI (1) | SI2685986T1 (es) |
TW (2) | TWI546301B (es) |
UA (1) | UA118248C2 (es) |
UY (1) | UY33958A (es) |
WO (1) | WO2012129084A2 (es) |
ZA (1) | ZA201307016B (es) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112013023774B1 (pt) * | 2011-03-18 | 2022-01-11 | Genzyme Corporation | Inibidores de glicosilceramida sintase |
AU2019222801B2 (en) * | 2012-09-11 | 2021-02-18 | Genzyme Corporation | Glucosylceramide synthase inhibitors |
JOP20130273B1 (ar) * | 2012-09-11 | 2021-08-17 | Genzyme Corp | مثبطات انزيم (سينثاز) غلوكوسيل سيراميد |
JO3713B1 (ar) * | 2013-03-15 | 2021-01-31 | Genzyme Corp | أشكال ملح (s)-كوينوكليدين-3-يل(2-(2-(4-فلوروفينيل)ثيازول-4-يل)بروبان-2-يل)كارباميت |
ES2968073T3 (es) | 2013-03-15 | 2024-05-07 | Genzyme Corp | Método de preparación de inhibidores de la glucosilceramida sintasa |
CN104418851A (zh) * | 2013-09-02 | 2015-03-18 | 上海龙翔生物医药开发有限公司 | 奎宁环衍生物的制备方法及纯化方法 |
CN117679415A (zh) * | 2013-12-11 | 2024-03-12 | 建新公司 | 葡糖神经酰胺合酶抑制剂 |
JP6836502B2 (ja) * | 2014-05-30 | 2021-03-03 | スプハエラ ファーマ ピーヴィーティー リミテッド | 抗結核薬としての新規な化合物 |
WO2016126572A2 (en) | 2015-02-02 | 2016-08-11 | The Regents Of The University Of Michigan | Glucosylceramide synthase inhibitors and therapeutic methods using the same |
TW201642855A (zh) * | 2015-03-10 | 2016-12-16 | 健臻公司 | 用於治療蛋白質病變之方法 |
CN108290894A (zh) * | 2015-07-01 | 2018-07-17 | 西北大学 | 被取代的4-甲基-吡咯并[1,2-a]嘧啶-8-甲酰胺类化合物及其调节葡糖脑苷脂酶活性的用途 |
US10167270B2 (en) | 2015-07-01 | 2019-01-01 | Northwestern University | Substituted quinazoline compounds and uses thereof for modulating glucocerebrosidase activity |
AR107483A1 (es) | 2016-01-29 | 2018-05-02 | Hanmi Pharm Ind Co Ltd | Conjugado de enzimas terapéuticas |
CA3018745A1 (en) | 2016-03-25 | 2017-09-28 | Genzyme Corporation | Biomarkers of proteopathies and uses thereof |
EP3318277A1 (en) | 2016-11-04 | 2018-05-09 | Institut du Cerveau et de la Moelle Epiniere-ICM | Inhibitors of glucosylceramide synthase for the treatment of motor neuron diseases |
CA3043709A1 (en) | 2016-11-14 | 2018-05-17 | Berg Llc | Methods for treating parkinson's disease |
EP3562821B9 (en) | 2016-12-28 | 2021-05-26 | Minoryx Therapeutics S.L. | Isoquinoline compounds, methods for their preparation, and therapeutic uses thereof in conditions associated with the alteration of the activity of beta galactosidase |
EP3562811B1 (en) | 2016-12-29 | 2022-03-16 | Minoryx Therapeutics S.L. | Heteroaryl compounds and their use |
CN108341822B (zh) * | 2017-01-23 | 2021-04-16 | 广州市恒诺康医药科技有限公司 | Fxr受体调节剂及其制备方法和应用 |
EP3709986B1 (en) * | 2017-11-14 | 2023-11-01 | Merck Sharp & Dohme LLC | Novel substituted biaryl compounds as indoleamine 2,3-dioxygenase (ido) inhibitors |
US20200339587A1 (en) | 2017-12-21 | 2020-10-29 | Lysosomal Therapeutics Inc. | Crystalline substituted cyclohexyl pyrazolo[1,5-a]pyrimidinyl carboxamide compound and therapeutic uses thereof |
JP7317721B2 (ja) * | 2018-01-31 | 2023-07-31 | 武田薬品工業株式会社 | 複素環化合物 |
US10519157B2 (en) * | 2018-02-09 | 2019-12-31 | X-Cutag Therapeutics, Inc. | Deuterated compounds for treating Fabry, Gaucher, Parkinson's and related diseases and conditions, and compositions and methods thereof |
KR102233530B1 (ko) * | 2018-11-22 | 2021-03-31 | (주)프로스테믹스 | 엑소좀 및 이의 다양한 용도 |
KR102342902B1 (ko) * | 2018-11-22 | 2021-12-24 | (주)프로스테믹스 | 엑소좀 및 이의 다양한 용도 |
KR102342901B1 (ko) * | 2018-11-22 | 2021-12-24 | (주)프로스테믹스 | 엑소좀 및 이의 다양한 용도 |
CN114040762A (zh) | 2019-02-04 | 2022-02-11 | 建新公司 | 使用葡糖神经酰胺合酶(gcs)的抑制剂治疗纤毛疾病 |
CN113710249A (zh) * | 2019-02-04 | 2021-11-26 | 建新公司 | 用于治疗溶酶体贮积症相关的症状和病症的方法 |
WO2020193746A1 (en) | 2019-03-28 | 2020-10-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting the survival of patients suffering from melanoma |
WO2021020363A1 (ja) * | 2019-07-29 | 2021-02-04 | 武田薬品工業株式会社 | 複素環化合物 |
WO2021081141A1 (en) | 2019-10-23 | 2021-04-29 | The Regents Of The University Of Michigan | Glucosylceramide synthase inhibitors and therapeutic methods using the same |
MX2022005679A (es) * | 2019-11-15 | 2022-06-27 | Yuhan Corp | Nuevos derivados que tienen una fraccion de 2,3-dihidro-1h-indeno o 2,3-dihidrobenzofurano o una sal farmaceuticamente aceptable de los mismos y composiciones farmaceuticas que los comprenden. |
US20220402909A1 (en) * | 2019-11-15 | 2022-12-22 | Yuhan Corporation | Novel derivatives having 1,2,3,4-tetrahydronaphthalene moiety or pharmaceutically acceptable salt thereof and pharmaceutical compositions comprising the same |
BR112022010127A2 (pt) | 2019-11-25 | 2022-09-06 | Gain Therapeutics Sa | Compostos de arila e heteroarila e usos terapêuticos dos mesmos em condições associadas à alteração da atividade de galatocerebrosidase |
IL293309A (en) | 2019-11-25 | 2022-07-01 | Gain Therapeutics Sa | Heteroaryl compounds and their therapeutic uses in conditions associated with altered beta-glucocerebrosidase activity |
CA3166777A1 (en) | 2020-02-03 | 2021-08-12 | Nigel Patrick Somerville CRAWFORD | Methods for treating neurological symptoms associated with lysosomal storage diseases |
CA3164707A1 (en) | 2020-02-03 | 2021-08-12 | Ana Maria Garcia Collazo | Combination therapy for treating mps1 |
WO2021214771A1 (en) | 2020-04-23 | 2021-10-28 | The Israel Institute of Biological Research (IIBR) | Glucosylceramide synthase inhibitors for prevention and treatment of viral diseases |
JP2023523454A (ja) | 2020-04-28 | 2023-06-05 | ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガン | グルコシルセラミド合成酵素のピリジン阻害剤及びそれらを使用する治療方法 |
AU2021311131A1 (en) | 2020-07-24 | 2023-03-23 | Genzyme Corporation | Pharmaceutical compositions comprising venglustat |
CN117222645A (zh) * | 2021-05-11 | 2023-12-12 | 柳韩洋行 | 对葡萄糖神经酰胺合成酶具有抑制活性的新颖的化合物或其药学上可接受的盐、其制备方法以及包含其的药物组合物 |
WO2023042177A1 (en) | 2021-09-20 | 2023-03-23 | Gt Gain Therapeutics Sa | Enantiomers of 5-((7-chloroisoquinolin-1-yl)amino)-n-(6-methoxy-1,2,3,4-tetrahydronaphthalen-2-yl)picolinamide |
WO2023239892A1 (en) * | 2022-06-10 | 2023-12-14 | Arkuda Therapeutics | Compounds for modulation of cd68 and uses thereof |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE640616A (es) | 1962-12-19 | |||
US3492397A (en) | 1967-04-07 | 1970-01-27 | Warner Lambert Pharmaceutical | Sustained release dosage in the pellet form and process thereof |
US4060598A (en) | 1967-06-28 | 1977-11-29 | Boehringer Mannheim G.M.B.H. | Tablets coated with aqueous resin dispersions |
US3538214A (en) | 1969-04-22 | 1970-11-03 | Merck & Co Inc | Controlled release medicinal tablets |
US4173626A (en) | 1978-12-11 | 1979-11-06 | Merck & Co., Inc. | Sustained release indomethacin |
WO1988002477A1 (en) * | 1986-10-03 | 1988-04-07 | Micro Motion, Inc. | Density insensitive coriolis mass flow rate meter |
IE62231B1 (en) | 1987-12-24 | 1995-01-11 | Wyeth John & Brother Ltd | Heterocyclic compounds |
US5549892A (en) | 1988-12-23 | 1996-08-27 | Genzyme Corporation | Enhanced in vivo uptake of glucocerebrosidase |
US5236838A (en) | 1988-12-23 | 1993-08-17 | Genzyme Corporation | Enzymatically active recombinant glucocerebrosidase |
IT1228293B (it) * | 1989-02-06 | 1991-06-07 | Angeli Inst Spa | Benzoderivati di composti eterociclici contenenti azoto. |
US5272071A (en) | 1989-12-22 | 1993-12-21 | Applied Research Systems Ars Holding N.V. | Method for the modification of the expression characteristics of an endogenous gene of a given cell line |
US5968502A (en) | 1991-11-05 | 1999-10-19 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
EP0747355A4 (en) | 1994-02-10 | 1997-04-09 | Yamanouchi Pharma Co Ltd | NEW CARBAMATES AND MEDICINAL PRODUCTS CONTAINING THEM |
JPH08198751A (ja) * | 1995-01-19 | 1996-08-06 | Yamanouchi Pharmaceut Co Ltd | カルバメート誘導体 |
KR19990067403A (ko) * | 1995-11-08 | 1999-08-16 | 이곤 이 버그 | 1-아자바이시클로헵탄 유도체 및 이의 약제학적용도 |
CA2305768A1 (en) | 1997-10-29 | 2000-02-24 | Genzyme Corporation | Compositions and methods for treating lysosomal storage disease |
US6953855B2 (en) * | 1998-12-11 | 2005-10-11 | Targacept, Inc. | 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof |
FR2791678B1 (fr) * | 1999-03-30 | 2001-05-04 | Synthelabo | Derives de 1,4-diazabicyclo [3.2.2] nonane-4-carboxylates et -carboxamides, leur preparation et leur application en therapeutique |
GB0010955D0 (en) * | 2000-05-05 | 2000-06-28 | Novartis Ag | Organic compounds |
PE20020719A1 (es) * | 2000-12-22 | 2002-10-11 | Almirall Prodesfarma Ag | Derivados de carbamato de quinuclidina como agentes antimuscarinicos m3 |
EP1231212B1 (en) * | 2001-02-06 | 2006-12-20 | Pfizer Products Inc. | Pharmaceutical compositions for the treatment of disorders of the CNS and other disorders |
JP2003267977A (ja) * | 2002-03-14 | 2003-09-25 | Yamanouchi Pharmaceut Co Ltd | キヌクリジン誘導体 |
ES2203327B1 (es) * | 2002-06-21 | 2005-06-16 | Almirall Prodesfarma, S.A. | Nuevos carbamatos de quinuclidina y composiciones farmaceuticas que los contienen. |
EP1534676B1 (en) * | 2002-07-17 | 2012-09-12 | Actelion Pharmaceuticals Ltd. | Piperidinetriol derivatives as inhibitors of glycosylceramide synthase |
JPWO2004011430A1 (ja) * | 2002-07-25 | 2005-11-24 | アステラス製薬株式会社 | ナトリウムチャネル阻害剤 |
SE0202598D0 (sv) * | 2002-09-02 | 2002-09-02 | Astrazeneca Ab | Alpha-7 Nicotinic receptor agonists and statins in combination |
EP2062595A1 (en) * | 2002-12-06 | 2009-05-27 | The Feinstein Institute for Medical Research | Inhibition of inflammation using alpha 7 receptor-binding cholinergic agonists |
GB0400812D0 (en) | 2004-01-14 | 2004-02-18 | Celltech R&D Ltd | Novel compounds |
JP2007186422A (ja) | 2004-01-28 | 2007-07-26 | Astellas Pharma Inc | アリールスルフィド誘導体 |
JP2008504282A (ja) * | 2004-06-23 | 2008-02-14 | ザ ファインスタイン インスティテュート フォー メディカル リサーチ | コリンレセプターの薬理活性により腸閉塞を処置する方法 |
CA2586761A1 (en) | 2004-11-10 | 2006-05-18 | Genzyme Corporation | Methods of treating diabetes mellitus |
WO2007100430A2 (en) * | 2006-01-27 | 2007-09-07 | Yale University | Cytisine and acetylcholine analogs and methods of treating mood disorders |
US7840109B2 (en) * | 2006-08-14 | 2010-11-23 | Adc Telecommunications, Inc. | Factory spliced cable assembly |
WO2009073564A1 (en) * | 2007-11-29 | 2009-06-11 | The Hospital For Sick Children | Compositions and methods for treating lysosomal disorders |
EP2320886B1 (en) * | 2008-07-28 | 2017-06-28 | Genzyme Corporation | Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease |
US20110237538A1 (en) * | 2008-08-06 | 2011-09-29 | Summit Corporation Plc | Treatment of lysosomal storage disorders and other proteostatic diseases |
EP2154136A1 (en) * | 2008-08-08 | 2010-02-17 | CHIESI FARMACEUTICI S.p.A. | Quinuclidine carbonate derivatives and medicinal compositions thereof |
WO2010091164A1 (en) * | 2009-02-06 | 2010-08-12 | Exelixis, Inc. | Inhibitors of glucosylceramide synthase |
WO2010091104A1 (en) * | 2009-02-06 | 2010-08-12 | Exelixis, Inc. | Glucosylceramide synthase inhibitors |
US9150803B2 (en) | 2009-06-09 | 2015-10-06 | Sundrop Fuels, Inc. | Systems and methods for biomass grinding and feeding |
MX356873B (es) | 2009-08-28 | 2018-06-18 | Sinai School Medicine | Uso farmacéutico de una esfingomielinasa ácida (asm) con aumento escalonada de la dosis para tratar la deficiencia de esfingomielinasa ácida. |
BR112013023774B1 (pt) * | 2011-03-18 | 2022-01-11 | Genzyme Corporation | Inibidores de glicosilceramida sintase |
-
2012
- 2012-03-16 BR BR112013023774-0A patent/BR112013023774B1/pt active IP Right Grant
- 2012-03-16 JP JP2013558205A patent/JP6117708B2/ja active Active
- 2012-03-16 CR CR20190034A patent/CR20190034A/es unknown
- 2012-03-16 DK DK12760259.7T patent/DK2685986T3/da active
- 2012-03-16 EP EP12760259.7A patent/EP2685986B1/en active Active
- 2012-03-16 LT LTEP12760259.7T patent/LT2685986T/lt unknown
- 2012-03-16 PL PL12760259T patent/PL2685986T3/pl unknown
- 2012-03-16 AU AU2012231275A patent/AU2012231275A1/en not_active Abandoned
- 2012-03-16 ES ES12760259T patent/ES2774293T3/es active Active
- 2012-03-16 BR BR122019017719-8A patent/BR122019017719B1/pt active IP Right Grant
- 2012-03-16 EP EP19207540.6A patent/EP3673906A1/en active Pending
- 2012-03-16 MX MX2013010710A patent/MX365245B/es active IP Right Grant
- 2012-03-16 CN CN201280024127.6A patent/CN103917094B/zh active Active
- 2012-03-16 MY MYPI2013003389A patent/MY173998A/en unknown
- 2012-03-16 RS RS20200222A patent/RS59963B1/sr unknown
- 2012-03-16 MX MX2018007961A patent/MX368340B/es unknown
- 2012-03-16 UY UY33958A patent/UY33958A/es not_active Application Discontinuation
- 2012-03-16 TW TW101109086A patent/TWI546301B/zh active
- 2012-03-16 CN CN201610884699.1A patent/CN107080747B/zh active Active
- 2012-03-16 UA UAA201312420A patent/UA118248C2/uk unknown
- 2012-03-16 HU HUE12760259A patent/HUE047888T2/hu unknown
- 2012-03-16 PT PT127602597T patent/PT2685986T/pt unknown
- 2012-03-16 RU RU2018104472A patent/RU2018104472A/ru not_active Application Discontinuation
- 2012-03-16 RU RU2013146550A patent/RU2645675C2/ru active
- 2012-03-16 WO PCT/US2012/029417 patent/WO2012129084A2/en active Application Filing
- 2012-03-16 PE PE2013002075A patent/PE20140412A1/es active IP Right Grant
- 2012-03-16 AR ARP120100873 patent/AR085425A1/es active IP Right Grant
- 2012-03-16 MA MA36299A patent/MA35023B1/fr unknown
- 2012-03-16 SI SI201231727T patent/SI2685986T1/sl unknown
- 2012-03-16 TW TW105121161A patent/TWI634119B/zh active
- 2012-03-16 KR KR1020137027592A patent/KR101987736B1/ko active IP Right Grant
- 2012-03-16 CA CA2830540A patent/CA2830540C/en active Active
-
2013
- 2013-09-17 NI NI201300083A patent/NI201300083A/es unknown
- 2013-09-17 DO DO2013000209A patent/DOP2013000209A/es unknown
- 2013-09-17 IL IL228514A patent/IL228514B/en active IP Right Grant
- 2013-09-17 CL CL2013002688A patent/CL2013002688A1/es unknown
- 2013-09-18 GT GT201300215A patent/GT201300215A/es unknown
- 2013-09-18 MX MX2019008428A patent/MX2019008428A/es unknown
- 2013-09-18 ZA ZA2013/07016A patent/ZA201307016B/en unknown
- 2013-09-18 US US14/030,725 patent/US9139580B2/en active Active
- 2013-10-17 CO CO13246820A patent/CO6801749A2/es active IP Right Grant
- 2013-10-17 EC ECSP13012978 patent/ECSP13012978A/es unknown
-
2014
- 2014-08-28 US US14/471,958 patent/US9126993B2/en active Active
-
2015
- 2015-08-25 US US14/835,402 patent/US20160207933A1/en not_active Abandoned
-
2016
- 2016-10-14 AU AU2016244305A patent/AU2016244305B2/en active Active
-
2017
- 2017-03-22 JP JP2017055577A patent/JP6420860B2/ja active Active
-
2019
- 2019-08-15 US US16/542,166 patent/US20200048266A1/en not_active Abandoned
-
2020
- 2020-02-11 HR HRP20200226TT patent/HRP20200226T1/hr unknown
-
2021
- 2021-04-27 US US17/242,016 patent/US20210261557A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NI201300083A (es) | Inhibidores de glucosilceramida sintasa | |
DOP2015000039A (es) | Inhibidores de glucosilceramida sintasa | |
AR082340A1 (es) | Metodos y composiciones para la terapia del cancer de higado | |
MX2016005556A (es) | Compuestos agonistas duales de gip-glp-1 y procedimientos. | |
MX2016003486A (es) | Inhibidores de glucosilceramida sintasa para el tratamiento de enfermedades. | |
WO2012104007A3 (de) | 7-azaindolderivate | |
SG10201804952QA (en) | Glucosylceramide synthase inhibitors | |
TN2015000427A1 (en) | Salt forms of (S)-Quinuclidin-3-yl (2-(2-(4-fluorophenyl)thiazol-4-yl)propan-2-yl)carbamate | |
CY1121859T1 (el) | Μεθοδος παρασκευης αναστολεων συνθασης γλυκοζυλοκεραμιδης | |
CR20140289A (es) | Derivados de quinolina como inhibidores de la enzima pde10a | |
TN2013000368A1 (en) | Glucosylceramide synthase inhibitors | |
UA112059C2 (uk) | Комбінована терапія із кріохірургією і іміквімодом для лікування актинічного кератозу (варіанти) | |
UA64452U (ru) | Применение гена аполипопротеида Е (апоЕ) в качестве средства для профилактики кардиосклероза |